SI3583103T1 - Rastlinski izvlečki, obogateni z ipolamiidnimi derivati, kot imunosupresivi za zdravljenje imunoloških motenj - Google Patents

Rastlinski izvlečki, obogateni z ipolamiidnimi derivati, kot imunosupresivi za zdravljenje imunoloških motenj

Info

Publication number
SI3583103T1
SI3583103T1 SI201830594T SI201830594T SI3583103T1 SI 3583103 T1 SI3583103 T1 SI 3583103T1 SI 201830594 T SI201830594 T SI 201830594T SI 201830594 T SI201830594 T SI 201830594T SI 3583103 T1 SI3583103 T1 SI 3583103T1
Authority
SI
Slovenia
Prior art keywords
ipolamide
immunosuppressants
derivatives
treatment
plant extracts
Prior art date
Application number
SI201830594T
Other languages
English (en)
Slovenian (sl)
Inventor
Cristiano Ruch Werneck Guimaraes
Carlos Eduardo Vitor
Lisandra Ravanelli Pessa
Romulo Dragani Reis
Alessandra Mascarello
Fernando Henrique De Souza Gama
Original Assignee
Ache Laboratorios Farmaceuticos S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos S.A. filed Critical Ache Laboratorios Farmaceuticos S.A.
Publication of SI3583103T1 publication Critical patent/SI3583103T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/92—Unsaturated compounds containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
SI201830594T 2017-02-17 2018-02-19 Rastlinski izvlečki, obogateni z ipolamiidnimi derivati, kot imunosupresivi za zdravljenje imunoloških motenj SI3583103T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102017003318-0A BR102017003318A2 (pt) 2017-02-17 2017-02-17 compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
EP18707229.3A EP3583103B1 (en) 2017-02-17 2018-02-19 Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders
PCT/BR2018/050037 WO2018148816A2 (en) 2017-02-17 2018-02-19 Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders

Publications (1)

Publication Number Publication Date
SI3583103T1 true SI3583103T1 (sl) 2022-07-29

Family

ID=61282932

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830594T SI3583103T1 (sl) 2017-02-17 2018-02-19 Rastlinski izvlečki, obogateni z ipolamiidnimi derivati, kot imunosupresivi za zdravljenje imunoloških motenj

Country Status (28)

Country Link
US (1) US12698265B2 (cg-RX-API-DMAC7.html)
EP (2) EP3583103B1 (cg-RX-API-DMAC7.html)
JP (2) JP7349362B2 (cg-RX-API-DMAC7.html)
KR (2) KR102882868B1 (cg-RX-API-DMAC7.html)
CN (1) CN110475768B (cg-RX-API-DMAC7.html)
AU (2) AU2018221956B2 (cg-RX-API-DMAC7.html)
BR (1) BR102017003318A2 (cg-RX-API-DMAC7.html)
CA (2) CA3052713A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002309A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019008891A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125187T1 (cg-RX-API-DMAC7.html)
DK (1) DK3583103T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP19058322A (cg-RX-API-DMAC7.html)
ES (1) ES2909387T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220377T1 (cg-RX-API-DMAC7.html)
IL (2) IL268732B2 (cg-RX-API-DMAC7.html)
LT (1) LT3583103T (cg-RX-API-DMAC7.html)
MX (2) MX2019009655A (cg-RX-API-DMAC7.html)
PE (2) PE20242300A1 (cg-RX-API-DMAC7.html)
PL (1) PL3583103T3 (cg-RX-API-DMAC7.html)
PT (1) PT3583103T (cg-RX-API-DMAC7.html)
RS (1) RS63162B1 (cg-RX-API-DMAC7.html)
SA (1) SA519402443B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907375VA (cg-RX-API-DMAC7.html)
SI (1) SI3583103T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200121T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018148816A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201906106B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
CN115304652A (zh) * 2022-07-25 2022-11-08 福建华闽晟业生物科技有限公司 一种利用巨菌草制备野芝麻新甙的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703543A (en) * 1969-11-05 1972-11-21 American Home Prod Hydroxamic acids of alicyclic amino acids
IL57433A (en) * 1978-06-03 1982-08-31 Inst Rech Chim Biolog Pharmaceutical compositions containing cyclopentane derivatives
DE3030477C2 (de) * 1980-08-12 1986-10-16 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Iridoid-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung
JPH0366682A (ja) * 1989-08-04 1991-03-22 Tsumura & Co 新規イリドイド誘導体
AU651849B2 (en) * 1990-10-09 1994-08-04 Tsumura & Co. Iridoid derivatives and their use as medicines
DE19644422C2 (de) 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
EP1145709A1 (de) * 2000-04-14 2001-10-17 Laboratoires Serobiologiques Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen
DE60336549D1 (de) * 2002-05-10 2011-05-12 Council Scient Ind Res Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure
EP1371372A1 (de) * 2002-06-08 2003-12-17 Cognis Iberia, S.L. Verwendung von Wirkstoffgemischen enthaltend Tocopherole und Extrakte des Harpagophytum procumbens zur Herstellung eines Medikamentes gegen rheumatische Arthritis
US7501222B2 (en) * 2005-06-24 2009-03-10 Dongjin Semichem Co., Ltd. Photoresist monomer polymer thereof and photoresist composition including the same
JP2008024670A (ja) * 2006-07-24 2008-02-07 Daiwa Kagaku Kogyo Kk 害虫駆除剤
US8552210B2 (en) * 2006-12-21 2013-10-08 E I Du Pont De Nemours And Company Hydrogenation of catmint oil
BRPI0700767B8 (pt) 2007-02-15 2021-05-25 Ache Laboratorios Farmaceuticos Sa composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo
KR101406933B1 (ko) * 2011-09-02 2014-06-12 동국대학교 산학협력단 라카아제를 이용한 새로운 효소형 시간-온도 이력지시계
CN103120699B (zh) * 2011-11-18 2017-04-19 天津市国际生物医药联合研究院 环烯醚萜类化合物在制备抗sars的药物中的应用
CN103690551A (zh) * 2013-07-18 2014-04-02 江苏大学 猪殃殃中环烯醚萜苷提取物及其提取方法和医药用途
DE102015102020A1 (de) * 2015-02-12 2016-08-18 Renate Wilmanowicz Immunologisch aktives Phyto-Gemisch und seine Anwendung bei der Prävention und in einem Verfahren zur Behandlung von Effloreszenzen
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas

Also Published As

Publication number Publication date
JP2023061959A (ja) 2023-05-02
CO2019008891A2 (es) 2020-01-17
CN110475768A (zh) 2019-11-19
IL268732B2 (en) 2024-12-01
SMT202200121T1 (it) 2022-07-21
PE20242300A1 (es) 2024-12-11
CL2019002309A1 (es) 2020-05-29
CY1125187T1 (el) 2023-06-09
BR112019017128A2 (pt) 2020-04-14
EP3583103A2 (en) 2019-12-25
IL268732B1 (en) 2024-08-01
AU2018221956A1 (en) 2019-08-29
AU2022201835A1 (en) 2022-04-07
US20200231561A1 (en) 2020-07-23
IL313974A (en) 2024-08-01
JP7349362B2 (ja) 2023-09-22
KR20250145126A (ko) 2025-10-13
BR102017003318A2 (pt) 2018-10-30
ES2909387T3 (es) 2022-05-06
RU2019129095A3 (cg-RX-API-DMAC7.html) 2021-10-27
JP7685540B2 (ja) 2025-05-29
RU2019129095A (ru) 2021-03-17
AU2018221956B2 (en) 2022-03-24
EP3583103B1 (en) 2022-01-12
EP4001270A1 (en) 2022-05-25
KR102882868B1 (ko) 2025-11-07
JP2020507607A (ja) 2020-03-12
RS63162B1 (sr) 2022-05-31
DK3583103T3 (da) 2022-03-14
SG11201907375VA (en) 2019-09-27
SA519402443B1 (ar) 2023-02-08
AU2022201835B2 (en) 2024-05-30
PL3583103T3 (pl) 2022-08-01
MX2022012282A (es) 2022-10-27
KR20190121790A (ko) 2019-10-28
WO2018148816A3 (en) 2018-10-18
PT3583103T (pt) 2022-03-25
NZ756074A (en) 2025-10-31
HRP20220377T1 (hr) 2022-07-08
IL268732A (en) 2019-10-31
WO2018148816A4 (en) 2019-01-03
CA3259255A1 (en) 2025-04-04
WO2018148816A2 (en) 2018-08-23
CA3052713A1 (en) 2018-08-23
US12698265B2 (en) 2026-08-04
MX2019009655A (es) 2020-07-24
ZA201906106B (en) 2020-08-26
PE20200449A1 (es) 2020-02-28
ZA202501840B (en) 2025-10-29
LT3583103T (lt) 2022-04-25
CN110475768B (zh) 2023-12-01
ECSP19058322A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
IL271085A (en) Bacteria for the treatment of disorders
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3383363T3 (da) Topiske farmaceutiske formuleringer til behandling af inflammatorisk-relaterede tilstande
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
LT3250210T (lt) Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
HUE060248T2 (hu) Eljárás növényi kivonatok elõállítására
HUE055351T2 (hu) 2,4-Tiazolidindion-származékok a központi idegrendszeri rendellenességek kezelésében
SI3697789T1 (sl) Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
DK3242888T3 (da) Opløselige fgfr3-atrapper til behandling af skeletvækstforstyrrelser
DK3380471T3 (da) Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser
EP3556769A4 (en) POLYMYXINE DERIVATIVE, MANUFACTURING PROCESS AND APPLICATION OF IT
HUE055463T2 (hu) Eljárás glükopiranozil-szubsztituált benzil-benzol-származékok elõállítására
HRP20181332T1 (hr) Derivati benzimidazola i njihovi farmaceutski pripravci, namijenjeni liječenju upalnih poremećaja
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112016026552A2 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
EP3347348A4 (en) PREPARATION OF 3-HYDROXY-3,6-DIMETHYLHEXAHYDROBENZOFURAN-2-ON AND DERIVATIVES THEREOF
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler
LT3341380T (lt) Chromono oksimo darinys, prasiskverbiantis į smegenis, skirtas levadopa sukeltos diskinezijos gydymui